Y

Yantai Dongcheng Biochemicals Co Ltd
SZSE:002675

Watchlist Manager
Yantai Dongcheng Biochemicals Co Ltd
SZSE:002675
Watchlist
Price: 12.32 CNY -1.91% Market Closed
Market Cap: 10.2B CNY
Have any thoughts about
Yantai Dongcheng Biochemicals Co Ltd?
Write Note

Net Margin
Yantai Dongcheng Biochemicals Co Ltd

3.2%
Current
6%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
3.2%
=
Net Income
90.8m
/
Revenue
2.9B

Net Margin Across Competitors

Country CN
Market Cap 10.2B CNY
Net Margin
3%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 311.8B USD
Net Margin
9%
Country US
Market Cap 140.7B USD
Net Margin
13%
Country US
Market Cap 115.7B USD
Net Margin
0%
Country US
Market Cap 102.7B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 78B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Yantai Dongcheng Biochemicals Co Ltd
Glance View

Market Cap
10.2B CNY
Industry
Biotechnology

In the bustling industrial city of Yantai, nestled along China's northeastern coast, Yantai Dongcheng Biochemicals Co Ltd has emerged as a formidable entity in the global biopharmaceutical landscape. Founded in 1998, the company has cleverly positioned itself at the confluence of modern science and traditional Chinese medicine. The hallmark of Dongcheng's business is its sophisticated production of active pharmaceutical ingredients (APIs), particularly heparin, which has earned it a prominent spot on the world stage. Through its agile manufacturing processes and commitment to quality, the company deftly navigates the intricate web of pharmaceutical demands, supplying essential components to global drug manufacturers who trust Dongcheng's expertise to ensure efficacy and safety in their final products. The financial engine of Yantai Dongcheng Biochemicals is powered by its vertically integrated model, which extends from raw material acquisition to finished product delivery. This strategic structure not only mitigates costs and enhances supply chain stability but also fortifies its competitive edge in the burgeoning healthcare market. The company has also expanded its portfolio to include a diverse array of biochemical products, catering to various therapeutic areas such as anticoagulation, oncology, and anti-infectives. This diversification not only spreads risk but also captures a broader spectrum of revenue opportunities. Moreover, Dongcheng's keen eye for innovation has seen it invest heavily in research and development, ensuring that it remains at the cutting edge of biopharmaceutical advancements. Through this strategic orchestration of resources and innovation, Dongcheng continues to deepen its footprint in the global market, underscoring its reputation as a trusted and dynamic player in the pharmaceutical industry.

Intrinsic Value
18.38 CNY
Undervaluation 33%
Intrinsic Value
Price
Y

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
3.2%
=
Net Income
90.8m
/
Revenue
2.9B
What is the Net Margin of Yantai Dongcheng Biochemicals Co Ltd?

Based on Yantai Dongcheng Biochemicals Co Ltd's most recent financial statements, the company has Net Margin of 3.2%.